Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update


ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Read this article:
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

Related Posts